LENZ Therapeutics (LENZ) news

Lenz Therapeutics, Inc.: BofA Global Research cuts to neutral from buy; cuts price objective to $7 from $31

Bank of America Global Research has revised its stance on Lenz Therapeutics, Inc. (Nasdaq: LENZ), downgrading the stock from "Buy" to "Neutral" and reducing its price target from $31 to $7 as of August 13, 2026. This adjustment follows a reassessment of the company’s growth trajectory, particularly…

CStone enters into commercialization pact with Arrotex

CStone Pharmaceuticals (HKEX: 2616) has not entered into a commercialization agreement with Arrotex for any of its drug candidates as of the latest available information. However, Arrotex Pharmaceuticals has recently entered into an exclusive license and commercialization agreement with LENZ…

Lenz Thera, Arrotx Pharma get license & commercialization pact

LENZ Therapeutics, Inc. (Nasdaq: LENZ) has entered into an exclusive license and commercialization agreement with Laboratoires Théa for the registration and commercialization of LNZ100 in Canada for the treatment of presbyopia. Under the terms of the agreement, LENZ is eligible to receive over $70…

Lenz Therapeutics - to receive upfront payment and profit share from Arrotex Vizz sales

Everest Medicines - to pay upfront, milestone payments and tiered royalties for LNZ100

Everest Medicines has entered into a licensing agreement with LENZ Therapeutics for the development and commercialization of LNZ100, a preservative-free, aceclidine-based eye drop for the treatment of presbyopia. Under the terms of the agreement, Everest Medicines is obligated to make upfront…